We observed SIGLEC1 expression increased at greater intensity as early as day 0-3 post infection in severe/critical versus mild/moderate patients, suggesting stronger and a more immediate type I IFN response in severe COVID-19 (Supplementary Fig. 15e). This evidence concerns the gene SIGLEC1 and COVID-19.